Tag Archives: Acute

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation

FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation Print this page November 28, 2018 — The U.S. Food and Drug Administration today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved… Read More »

Which Drug Combination Works Best to Reduce Acute COPD Exacerbations?

November 20, 2018 Share this content: A higher blood eosinophil count was associated with a greater protective effect of ICS/LABA/LAMA against severe acute COPD exacerbations. A combination of inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA)/long-acting muscarinic receptor antagonist (LAMA) is possibly more effective than a LABA/LAMA combination or single long-acting bronchodilator therapy in reducing the risk for… Read More »